Status:
UNKNOWN
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
Lead Sponsor:
University of Tennessee
Collaborating Sponsors:
Vanderbilt University Medical Center
AstraZeneca
Conditions:
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to c...
Eligibility Criteria
Inclusion
- Receiving cancer care at Vanderbilt University Medical Center
- Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), or multiple myeloma (MM)
- Initiating an oral anticancer agent, either for the first time or a change from previous oral agent
- Diagnosis of 2 chronic conditions, including at least one of the following: diabetes, hypertension, hyperlipidemia, congestive heart failure, depression/anxiety, gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease
- Patients taking at least two chronic medications, including at least one medication for one of the conditions listed above.
- Willing and able to sign informed consent.
Exclusion
- Cannot communicate in English
- Concurrent diagnosis of type 1 diabetes or human immunodeficiency virus
Key Trial Info
Start Date :
February 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04663100
Start Date
February 8 2021
End Date
December 31 2023
Last Update
December 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232